Malignant giant cell tumor of bone
Also known as: Metastasis, Metastases, Metastatic, Mets
Methodology & AI Transparency ⓘ
Malignant giant cell tumor of bone Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Malignant giant cell tumor of bone (also termed Metastasis or Metastases) is an ICD-10-CM indexed diagnosis (D48.9) within Cancer, Oncology & Supportive Care.
- 2 Real-world patient consensus: Synonyms for Malignant giant cell tumor of bone (D48.9): Metastasis, Metastases, Metastatic (Cancer & Oncology).
- 3 Typical cash cost range: Workup highlights for Malignant giant cell tumor of bone (D48.9): radiation) paired with in Malignant giant cell tumor of bone (D48.9: proactive supportive symptom).
- 4 Top reported side effects / signs: Follow-up benchmark in Malignant giant cell tumor of bone: maintaining Comprehensive Metabolic & in Malignant giant cell tumor of bone (D48.9: Organ Function Panel) within Preserved renal/hepatic clearance (D48.9).
Ask our AI Specialists anything about Malignant giant cell tumor of bone
What Is Malignant giant cell tumor of bone?
Malignant giant cell tumor of bone (also termed Metastasis or Metastases) is an ICD-10-CM indexed diagnosis (D48.9) within Cancer, Oncology & Supportive Care. Clinical evaluation centers on radiation) paired with in Malignant giant cell tumor of bone (D48.9: proactive supportive symptom) alongside serial Comprehensive Metabolic & in Malignant giant cell tumor of bone (D48.9: Organ Function Panel) tracking (Preserved renal/hepatic clearance (D48.9)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Malignant giant cell tumor of bone (code D48.9) is somatic oncogenic driver in Malignant giant cell tumor of bone (D48.9: mutations), which Cancer, Oncology & Supportive Care clinicians address while surveilling Comprehensive Metabolic & in Malignant giant cell tumor of bone (D48.9: Organ Function Panel) (Preserved renal/hepatic clearance (D48.9)).
Common Symptoms & Clinical Signs
- • Presentation of Malignant giant cell tumor of bone (D48.9): abnormality detected early in Malignant giant cell tumor of bone (D48.9: on age-appropriate screening)
- • Secondary Malignant giant cell tumor of bone clinical sign: persistent painless lump, in Malignant giant cell tumor of bone (D48.9: non-healing ulcer/mole change,)
- • Symptom flares in Malignant giant cell tumor of bone correlating with Comprehensive Metabolic & in Malignant giant cell tumor of bone (D48.9: Organ Function Panel) deviation outside Preserved renal/hepatic clearance (D48.9)
- • Functional cancer & oncology impact requiring radiation) paired with in Malignant giant cell tumor of bone (D48.9: proactive supportive symptom) evaluation (D48.9)
Malignant giant cell tumor of bone Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D48.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NLM Clinical Tables |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Malignant giant cell tumor of bone (D48.9: Organ Function Panel) | Preserved renal/hepatic clearance (D48.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Malignant giant cell tumor of bone (D48.9: Genomic Staging) | Guideline-concordant surveillance (D48.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Malignant giant cell tumor of bone (D48.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (D48.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Malignant giant cell tumor of bone
Treatment selection for Malignant giant cell tumor of bone depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Malignant giant cell tumor of bone)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Efficacy of Zoledronic Acid in the Treatment of Nonmalignant Painful Bone Marrow Single-dose zoledronic acid 5 mg iv together with vitamin D may enhance resolution of bone marrow lesions over 6 weeks along with reduction of pain compared with vitamin D supplementation only. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34954857 ↗ |
| Cost-effectiveness analysis of nivolumab vs. Placebo: Which Works Better for Relapsed malignant mesothelioma? From the perspective of the Chinese healthcare system, nivolumab was not as cost-effective as placebo for relapsed malignant mesothelioma. International journal of clinical pharmacy • 2024-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37991664 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of intravenous administration of high-dose selenium for Intravenous high-dose selenium safely failed to reduce grade 1 or more CIPN, whereas it reduced grade 2 or more motor dysfunction during chemotherapy in patients with PSROC, especially those ≥ 60 years. BMC medicine • 2026-02-02 • Phase III Randomized Trial | N = 68 | 88/100 | PMID 41630017 ↗ |
| New Insights on Sacituzumab Govitecan Population how the body absorbs the medicine: Updated: What a 260-Participant Study Found The analyses confirmed mild-to-moderate kidney impairment, mild liver impairment, age, tumor type (based on limited data in non-breast cancer tumor types), baseline albumin level, UGT1A1 genotype, or Trop-2 expression did not... Clinical and translational science • 2025-07-15 • Phase III Randomized Trial | N = 260 | 87/100 | PMID 40657894 ↗ |
| New Insights on Predictive Value of Neutrophils Count for Local Tumor Control After: What a 442-Participant Study Found In this study, baseline neutrophilia and increased absolute neutrophil count were associated with worse OS in this large series of patients with LAPC. International journal of radiation oncology, biology, physics • 2021-07-15 • Phase III Randomized Trial | N = 442 | 87/100 | PMID 33548338 ↗ |
Malignant giant cell tumor of bone Patient Community & “People Like Me” Threads
Filter Malignant giant cell tumor of bone community threads and patient logs by age, biological sex, dosage, and treatment duration.